Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

用于治疗传染病的治疗剂的合成

• 批准号: 10901810
• 负责人: MARK MIDDLETON
• 金额: $ 10万
• 依托单位: STARKS ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-16 至 2019-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10901810
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Clinical Research; Communicable Diseases; Contractor; Contracts; Diagnosis; Disease; Good Manufacturing Process; HIV; Immune; Immunology; In Vitro; Local Microbicides; Mediating; Microbiology; National Institute of Allergy and Infectious Disease; Phase; Prevention; Regulation; Research; Research Support; Resources; Testing; Therapeutic; Therapeutic Agents; United States Dept. of Health and Human Services; United States National Institutes of Health; chemical synthesis; clinical diagnostics; infectious disease treatment; microbicide; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of AIDS has a requirement for the synthesis of therapeutics directed against HIV and other infectious diseases as well as agents to serve and anti-HIV topical microbicides. This initiative provides the resources for the synthesis of microbicides and compounds for the treatment of HIV, and other infectious diseases of relevance to the research agenda of NIAID. The contract will synthesize chemicals, in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations if necessary, in quantities needed for testing in in vitro screens, animals, or early Phase I clinical studies.

卫生与公共服务部国家卫生研究院（NIH）国家过敏和传染病研究所（NIAID）（DHHS）（DHHS）支持与对微生物学和免疫学的基本理解有关的研究，从而导致疫苗，治疗，治疗和医学诊断，以治疗，治疗，治疗，诊断和免疫诊断和免疫诊断和免疫诊断。艾滋病的NIAID划分需要针对HIV和其他传染病的理论综合，以及用于服务和抗HIV局部杀菌剂的药物。该倡议为合成菌心和化合物的艾滋病毒治疗以及其他与NIAID研究议程相关的传染病提供了资源。合同将根据FDA目前的良好制造实践（CGMP）法规合成化学品，以测试体外筛查，动物或早期I期临床研究所需的数量。